Drug Interaction Report

Ganaxolone has a moderate potential interaction with Alcoholism.

Ganaxolone can cause somnolence and sedation; other CNS depressants (including alcohol) could potentiate these effects. Caution is advised when using this agent in patients with alcohol disorders. Patients should be monitored for somnolence and sedation, and patients should be advised not to drive or operate machinery until they know how ganaxolone will affect them.

Ganaxolone has a moderate potential interaction with Depression.

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

Ganaxolone has a moderate potential interaction with Liver Disease.

The effect of liver dysfunction on the pharmacokinetics of ganaxolone has not been studied; since this drug undergoes hepatic clearance, liver dysfunction can increase ganaxolone exposure. Caution is advised in patients with impaired liver function; they should be monitored for side effects and may require a reduced dosage of ganaxolone.

Ganaxolone has a moderate potential interaction with Psychosis.

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

Ganaxolone has a minor potential interaction with Renal Dysfunction.

The effect of renal dysfunction on the pharmacokinetics of ganaxolone has not been studied; however, since renal excretion is a minor elimination pathway, impaired renal function is unlikely to increase ganaxolone exposures significantly. Caution is recommended in these patients.